LifeMD, Inc. (NASDAQ:LFMD) CEO Justin Schreiber Sells 25,000 Shares

LifeMD, Inc. (NASDAQ:LFMD) CEO Justin Schreiber sold 25,000 shares of the company’s stock in a transaction on Thursday, January 2nd. The shares were sold at an average price of $5.19, for a total value of $129,750.00. Following the transaction, the chief executive officer now directly owns 2,703,715 shares in the company, valued at $14,032,280.85. This trade represents a 0.92 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website.

Justin Schreiber also recently made the following trade(s):

• On Monday, December 2nd, Justin Schreiber sold 25,000 shares of LifeMD stock. The stock was sold at an average price of $6.52, for a total value of $163,000.00.

LifeMD Price Performance

LFMD opened at $5.10 on Thursday. The company has a fifty day simple moving average of $5.57 and a 200 day simple moving average of $5.55. The company has a quick ratio of 0.78, a current ratio of 0.83 and a debt-to-equity ratio of 10.83. The stock has a market cap of $220.89 million, a P/E ratio of -7.97 and a beta of 1.49. LifeMD, Inc. has a 12 month low of $3.99 and a 12 month high of $12.88.

Wall Street Analyst Weigh In

LFMD has been the subject of several analyst reports. Cantor Fitzgerald reiterated an “overweight” rating and set a $15.00 price target on shares of LifeMD in a research report on Friday, September 20th. Mizuho began coverage on shares of LifeMD in a report on Wednesday, December 4th. They set a “neutral” rating and a $7.00 target price for the company. KeyCorp cut their price target on LifeMD from $10.00 to $7.00 and set an “overweight” rating on the stock in a research note on Wednesday. Lake Street Capital started coverage on LifeMD in a research note on Tuesday, December 10th. They set a “buy” rating and a $12.00 price objective for the company. Finally, HC Wainwright reissued a “buy” rating and issued a $12.00 target price on shares of LifeMD in a research note on Monday, November 11th. One investment analyst has rated the stock with a hold rating and six have given a buy rating to the stock. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $11.14.

Hedge Funds Weigh In On LifeMD

Institutional investors have recently modified their holdings of the business. State Street Corp increased its stake in LifeMD by 20.0% during the 3rd quarter. State Street Corp now owns 1,155,495 shares of the company’s stock worth $6,055,000 after purchasing an additional 192,861 shares in the last quarter. Royce & Associates LP boosted its holdings in shares of LifeMD by 14.6% in the third quarter. Royce & Associates LP now owns 901,041 shares of the company’s stock valued at $4,721,000 after buying an additional 114,710 shares during the period. Los Angeles Capital Management LLC increased its position in shares of LifeMD by 852.6% during the third quarter. Los Angeles Capital Management LLC now owns 121,585 shares of the company’s stock worth $637,000 after acquiring an additional 108,822 shares in the last quarter. Bank of New York Mellon Corp raised its holdings in shares of LifeMD by 63.6% during the second quarter. Bank of New York Mellon Corp now owns 234,583 shares of the company’s stock worth $1,609,000 after acquiring an additional 91,183 shares during the period. Finally, Geode Capital Management LLC lifted its position in LifeMD by 11.4% in the 3rd quarter. Geode Capital Management LLC now owns 819,233 shares of the company’s stock valued at $4,293,000 after acquiring an additional 83,598 shares in the last quarter. Institutional investors own 35.52% of the company’s stock.

About LifeMD

LifeMD, Inc operates as a direct-to-patient telehealth company that connects consumers to healthcare professionals for medical care in the United States. The company offers telehealth platform comprising RexMD, a men's telehealth brand that provides access to virtual medical treatment for a variety of men's health needs from licensed physician; ShapiroMD that provides virtual medical treatment, prescription medications, patented doctor formulated OTC products, topical compounded medications, and medical devices treating male and female hair loss; NavaMD, a female-oriented tele-dermatology that offers virtual medical treatment from dermatologists and other providers; and prescription oral and compounded topical medications to treat aging and acne; and Cleared which provides personalized treatments for allergy, asthma and immunology, including in-home tests for both environmental and food allergies, prescriptions for allergies and asthma and immunotherapies for treating chronic allergies.